Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy (CisPemXetSrg)

This study has been terminated.
(Investigator left site)
Information provided by:
Medical University of South Carolina Identifier:
First received: June 13, 2011
Last updated: July 24, 2012
Last verified: July 2012

This study is open to patients that have been diagnosed with non-squamous Stage III Non Small Cell Lung Cancer (NSCLC) and will have surgery to remove the tumor.

The purpose of this study is to:

  • Test a combination of two chemotherapeutic drugs along with radiation therapy, when given prior to surgery and see what effects (good or bad) it has on someone with this type of cancer. Chemotherapeutic drugs selectively destroy diseased cancer cells and tissues.
  • Test the safety of different dose levels of radiation when given with each combination of chemotherapy;
  • Determine what side effects are associated with combining radiation with these two chemotherapy combinations.

Condition Intervention Phase
Nonsquamous Nonsmall Cell Neoplasm of Lung
Nonsmall Cell Lung Cancer Stage III
Drug: Pemetrexed
Drug: Carboplatin
Radiation: Radiation Therapy
Drug: Cisplatin
Procedure: Lobectomy
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed With Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients With Non-Squamous Non Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Safety and tolerability
    Determine the safety and tolerability of concurrent chemotherapy with Cisplatin/ Pemetrexed or Carboplatin/Pemetrexed and dose escalated radiation therapy followed by lobectomy.

Secondary Outcome Measures:
  • Response rate, overall survival and progression free survival

    Evaluate the following:

    • Response Rate after concurrent chemoradiation therapy.
    • Overall Survival (OS).
    • Progression Free Survival (PFS)

Enrollment: 48
Study Start Date: May 2011
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
  1. Patients will be given the drugs pemetrexed and carboplatin
  2. Radiation
  3. Participants evaluated for response
  4. Lobectomy surgery
Drug: Pemetrexed
Pemetrexed by vein every 21 days for 3 cycles
Drug: Carboplatin
Carboplatin by vein Every 21 days for 3 cycles
Radiation: Radiation Therapy
Radiation treatment 5 days a week for 5-6 weeks.
Procedure: Lobectomy
Experimental: Arm B
  1. Patients will be given the drugs pemetrexed and cisplatin
  2. Radiation
  3. Participants evaluated for response
  4. Lobectomy surgery
Drug: Pemetrexed
Pemetrexed by vein every 21 days for 3 cycles
Drug: Cisplatin
Cisplatin by vein every 21 days for 3 cycles
Radiation: Radiation Therapy
Radiation treatment 5 days a week for 5-6 weeks.
Procedure: Lobectomy
Surgery to remove a portion of the lung where the tumor is located.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically and cytologically confirmed non-squamous NSCLC.
  • Resectable T3, and or N2 disease (T3N1, and resectable T1-3N2 multi-station non-bulky with no nodal station being more than 2 cm on preoperative workup, T4N0-1
  • Resectable T3 includes patients with a satellite lesion in the same lobe as the primary.
  • Male or Female, aged > or = 18 years and be able to give informed consent.
  • Tumor should be technically operable with a lobectomy, bilobectomy or a sleeve resection.
  • Patient should be medically operable
  • ECOG Performance Status 0 or 1.
  • Adequate bone marrow, hepatic and renal function assessed within 28 days
  • Signed informed consent.
  • Women of childbearing potential should have negative pregnancy test prior to enrollment to study.
  • Men with partners in the childbearing age group and women of childbearing potential must use effective contraception while on treatment and for 6 months thereafter.
  • The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.
  • The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.
  • Patients must have a negative MRI or CT Scan of the brain.

Exclusion Criteria:

  • Patients who have had chemotherapy or radiation therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Patients may not be receiving any other investigational agents.
  • History of allergic reactions attributed to compounds or other agents used in study.
  • Pregnant or lactating women.
  • Male patients with female sexual partners in the reproductive age group who refuse to use effective methods of contraception will be excluded from the trial.
  • Patients with concurrent serious infections.
  • Patients with an unstable or serious concurrent medical condition are excluded.
  • Presence of third space fluid which cannot be controlled by drainage.
  • Weight loss > 10 percent from baseline weight.
  • HIV-positive patients on combination antiretroviral therapy are ineligible
  • Patients with hypercalcemia will be excluded.
  • Patients who require a pneumonectomy will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01373463

United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
  More Information

Responsible Party: George Simon, MD, Hollings Cancer Cetner Medical University of South Carolina Identifier: NCT01373463     History of Changes
Other Study ID Numbers: 101466
Study First Received: June 13, 2011
Last Updated: July 24, 2012

Keywords provided by Medical University of South Carolina:

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on May 24, 2017